RPH-002 (cetuximab biosimilar) / R-Pharm - LARVOL DELTA

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P1 | N=118 | Completed | Sponsor: R-Pharm

New P1 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P3 | N=161 | Active, not recruiting | Sponsor: R-Pharm

New P3 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Results of a phase I clinical trial of cetuximab biosimilar (RPH-002). (ASCO 2025) - "The objective of the study was to establish the equivalence of the pharmacokinetic (PK) properties, safety and immunogenicity of RPH-002 and Erbitux, as well as to evaluate the pilot efficacy in patients with advanced HNSCC in combination with docetaxel and cisplatin as 1st line therapy. RPH-002 has similar PK, safety and efficacy profiles in comparison with Erbitux."

Clinical • P1 data • Colorectal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • HER-2